首页> 外国专利> COMPOSITION FOR IMPROVING EFFICACY OF L-DOPA TREATMENT

COMPOSITION FOR IMPROVING EFFICACY OF L-DOPA TREATMENT

机译:改善左旋多巴治疗效率的组合物

摘要

The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.
机译:本发明涉及用于(a)治疗患有帕金森氏病的哺乳动物的运动技能受损的组合物; (b)改善左旋多巴(L-DOPA)在患有帕金森氏病的哺乳动物中治疗运动技能受损的功效;和/或(c)在患有帕金森氏病的哺乳动物的运动技能受损的治疗中,减少L-DOPA相关的副作用,最好是从杂乱形,肌张力障碍和运动障碍运动中选择的非自愿运动,包括与下列药物合用:主题L-DOPA和包含治疗有效量的组合物:(i)尿苷,胞苷或其盐,磷酸盐,酰基衍生物或酯中的至少一种; (ii)二十二碳六烯酸(22:6; DHA),二十碳五烯酸(20:5; EPA)和二十二碳五烯酸(22:5; DPA)中的至少一种; (iii)胆碱或其盐或酯; (iv)至少一种选自维生素B6,B9和B12的维生素B。

著录项

  • 公开/公告号US2020108036A1

    专利类型

  • 公开/公告日2020-04-09

    原文格式PDF

  • 申请/专利权人 N.V. NUTRICIA;

    申请/专利号US201916706337

  • 申请日2019-12-06

  • 分类号A61K31/198;A61K31/7072;A61K31/714;A61K31/519;A61K31/4415;A61K47/24;A61K31/375;A61K31/14;A61K31/202;A61P25/16;

  • 国家 US

  • 入库时间 2022-08-21 11:19:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号